WhaleCreep

Casdin Capital, LLC 13F holdings, Q2 2022

Hedge fundSEC filingsCompare with another fundHoldings as of 2022-06-30, filed 2022-08-15

Casdin Capital, LLC disclosed 40 US equity positions worth $1.2bn in its Q2 2022 13F filing. Its largest position is EQRX INC at 15.7% of the reported book, followed by ALNY and BLFS. Versus Q1 2022 it opened 5 new positions, added to 2, reduced 19 and exited 12.

$1.2bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
40
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
15.7%
Largest position
The largest single position as a share of the reported equity book.
68.0%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
15
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2022: 5 new, 2 added, 19 reduced, 12 exited

40 rows
EQRX INC no ticker–15.7%$185m39.53m0.0%held
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare9.9%$117m805,000−19%reduced
BLFS BIOLIFE SOLUTIONS INCHealthcare8.8%$104m7.57m0.0%held
RLAY RELAY THERAPEUTICS INCHealthcare5.8%$68.1m4.07m+5.5%added
MXCT MAXCYTE INCHealthcare5.6%$66.1m13.97m0.0%held
2655787D BLUEPRINT MEDICINES CORP–4.9%$58.1m1.15m−26%reduced
SLGCUSD SOMALOGIC INC–4.7%$56.0m12.39m0.0%held
FATE FATE THERAPEUTICS INCHealthcare4.4%$52.0m2.10m−38%reduced
SRPT SAREPTA THERAPEUTICS INCHealthcare4.1%$48.7m650,000−19%reduced
VERVE THERAPEUTICS INC no ticker–4.1%$48.0m3.14m0.0%held
RVMD REVOLUTION MEDICINES INCHealthcare3.9%$46.2m2.37m0.0%held
DNLI DENALI THERAPEUTICS INCHealthcare3.7%$44.1m1.50m0.0%held
IPSC CENTURY THERAPEUTICS INCHealthcare2.3%$26.9m3.21m0.0%held
ABSI ABSCI CORPORATIONHealthcare2.2%$25.6m7.72m0.0%held
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–2.2%$25.6m800,000−40%reduced
WGS GENEDX HOLDINGS CORPHealthcare1.8%$20.7m16.44m+229%added
TNYA TENAYA THERAPEUTICS INCHealthcare1.7%$20.2m3.59m0.0%held
EXK EXACT SCIENCES CORPBasic Materials1.5%$17.7m450,000−66%reduced
TWST TWIST BIOSCIENCE CORPHealthcare1.5%$17.5m500,000−43%reduced
AGIO AGIOS PHARMACEUTICALS INCHealthcare1.5%$17.4m785,000−62%reduced
TNGX TANGO THERAPEUTICS INCHealthcare1.3%$15.9m3.50m−36%reduced
BEAM BEAM THERAPEUTICS INCHealthcare1.2%$14.5m375,000−54%reduced
GH GUARDANT HEALTH INCHealthcare0.9%$11.0m272,500−35%reduced
KRTX KARUNA THERAPEUTICS INC–0.9%$10.8m85,000–new
TSVT* 2SEVENTY BIO INC–0.7%$8.1m614,7540.0%held
ABCL ABCELLERA BIOLOGICS INCHealthcare0.7%$8.0m750,000–new
EXAIEUR EXSCIENTIA PLC–0.6%$7.2m663,900−7.0%reduced
MRTXEUR MIRATI THERAPEUTICS INC–0.6%$6.5m97,000−5.4%reduced
GLUE MONTE ROSA THERAPEUTICS INCHealthcare0.4%$4.9m510,882−47%reduced
CLDX CELLDEX THERAPEUTICS INC NEWHealthcare0.4%$4.4m165,000–new
PMVP PMV PHARMACEUTICALS INCHealthcare0.4%$4.3m300,000–new
SGMOQ SANGAMO THERAPEUTICS INCHealthcare0.4%$4.1m1.00m–new
FDMT 4D MOLECULAR THERAPEUTICS INHealthcare0.3%$3.9m555,4550.0%held
SINGULAR GENOMICS SYSTEMS IN no ticker–0.3%$3.3m865,722−40%reduced
MAGENTA THERAPEUTICS INC no ticker–0.2%$2.9m2.42m−13%reduced
ORIC ORIC PHARMACEUTICALS INCHealthcare0.2%$2.7m601,5150.0%held
NVTA1EUR INVITAE CORP–0.2%$2.5m1.04m−91%reduced
SCIENCE 37 HOLDINGS INC no ticker–0.04%$452k225,000−88%reduced
KRON1USD KRONOS BIO INC–0.04%$451k123,839−79%reduced
LIANY LIANBIO–0.04%$446k206,4150.0%held

Exited since Q1 2022

12 rows
PACB PACIFIC BIOSCIENCES CALIF IN3.3%$72.7m
CDNA CAREDX INC1.9%$42.7m
ONC BEIGENE LTD1.3%$28.3m
DMTKQ DERMTECH INC1.1%$25.6m
GINKGO BIOWORKS HOLDINGS INC no ticker0.8%$16.9m
ADPT ADAPTIVE BIOTECHNOLOGIES COR0.6%$13.9m
SEER SEER INC0.5%$12.2m
GBIOGBX GENERATION BIO CO0.4%$9.7m
ZLAB ZAI LAB LTD0.3%$6.6m
CDXS CODEXIS INC0.3%$6.2m
RXRX RECURSION PHARMACEUTICALS IN0.2%$3.9m
DECIBEL THERAPEUTICS INC no ticker0.04%$1.0m

Sector mix

  • Healthcare63.4%
  • Unclassified35.1%
  • Basic Materials1.5%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters